Inclusion criteria :

          -  Metastatic disease progression fulfilling both of the following 2 criteria:

               1. Having progressive disease during or after platinum-based chemotherapy (at least
                  2 cycles). Maintenance therapy following platinum-based chemotherapy is not
                  considered as a separate regimen. Adjuvant/neoadjuvant treatment for a patient
                  who had a relapse with metastatic disease during or within 6 months of completing
                  treatment will be considered as first-line treatment.

                  AND

               2. Having progressive disease during or after 1 immune checkpoint inhibitor
                  (anti-PD1/PD-L1); this could be given as monotherapy or in combination with
                  platinum-based chemotherapy (whatever the order).

          -  Participants with carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 5
             expression of ≥2+ in archival tumor sample (or if not available, fresh biopsy sample)
             involving at least 50 % of the tumor cell population as demonstrated prospectively by
             central laboratory via immune histochemistry (IHC).

          -  At least one measurable lesion by RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  A female participant who agrees to use effective contraceptive methods during and for
             at least 7 months after the last dose of study intervention.

          -  A male participant who agrees to use effective contraception methods during and for at
             least 4 months after the last dose of study intervention

          -  Signed informed consent

        Exclusion criteria:

        Participants are excluded from the study if any of the following criteria apply:

          -  Patients with untreated brain metastases and history of leptomeningeal disease.

          -  Significant concomitant illnesses that would impair the patient's participation in the
             study or interpretation of the results.

          -  History within the last 3 years of an invasive malignancy other than the one treated
             in this study, with the exception of resected/ablated basal or squamous-cell carcinoma
             of the skin or carcinoma in situ of the cervix, or other local tumors considered cured
             by local treatment.

          -  Non-resolution of any prior treatment related toxicity to < grade 2 according to NCI
             CTCAE V5.0, except for alopecia, vitiligo and active thyroiditis controlled with
             hormonal replacement therapy

          -  History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known
             HIV disease requiring antiretroviral treatment, or unresolved viral hepatitis

          -  Previous history of and/or unresolved corneal disorders. The use of contact lenses is
             not permitted.

          -  Radiographic evidence of major airway or blood vessel invasion or intratumor
             cavitation

          -  History of uncontrolled hereditary or acquired thrombotic disorder or history of
             aneurism.

          -  Major surgery within 28 days prior to Day 1/first IMP infusion,. Postoperative
             bleeding complications or wound complications from a surgical procedure performed in
             the last 2 months.

          -  History of gross hemoptysis within 2 months before the first administration of study
             intervention.

          -  Clinically relevant congestive heart failure (CHF; NYHA II-IV, or LVEF less than 50%)
             or symptomatic or poorly controlled cardiac arrhythmia.

          -  Any arterial thrombotic event within 6 months before the first administration of study
             intervention.

          -  Uncontrolled arterial hypertension (systolic ≥150 mmHg or diastolic ≥90 mmHg) despite
             standard medical management.

          -  Serious or nonhealing wound, skin ulcer, or bone fracture within 28 days before the
             first administration of study intervention.

          -  Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to first
             administration of study intervention.

          -  Significant bleeding disorders, vasculitis, or Grade 3-4 gastrointestinal (GI)
             bleeding within 3 months before the first administration of study intervention.

          -  Bowel obstruction, history or presence of inflammatory enteropathy or extensive
             intestinal resection Crohn's disease, ulcerative colitis, or chronic diarrhea.

          -  Medical condition requiring concomitant administration of a medication with a narrow
             therapeutic window and metabolized by CYP450 or a strong CYP3A inhibitor

          -  Concurrent treatment with any other anticancer therapy

          -  No more than 1-line previous chemotherapy in metastatic setting

          -  Prior treatment with ramucirumab or docetaxel

          -  Prior therapy targeting CEACAM5 or maytansinoid treatment (DM1 or DM4 antibody-drug
             conjugate)

          -  Contraindication to use of corticosteroid premedication

          -  Current therapeutic anticoagulation with warfarin, low-molecular-weight heparin, or
             similar agents. Patients receiving prophylactic, low-dose anticoagulation therapy are
             eligible

          -  Previous enrollment in this study, current participation in any other clinical study
             involving an investigational study treatment, or any other type of medical research

          -  Poor bone marrow, liver or kidney functions

          -  Urine dipstick or routine analysis indicating proteinuria of 2+ or higher, unless a 24
             hour urine collection demonstrates <1000 mg of protein.

          -  Sensitivity to any of the study interventions, or components thereof, or drug or other
             allergy that, in the opinion of the Investigator, contraindicates participation in the
             study.Most important exclusion criteria for potential participants

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.